Clinical trials: Throat Carcinoma
Nasopharyngeal Carcinoma
Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer.
- Trial name
- NCT03267498
- Testing
- Nivolumab, Cisplatin, Radiation Therapy
- Where
- 2 sites in United States, Singapore
- Volunteers
- 40 people
- Sponsor
- Sue Yom
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
This phase II trial investigates how well sodium thiosulfate works in preventing ototoxicity (hearing loss/damage) in patients with squamous cell cancer of the head and neck that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04541355
- Testing
- Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hyunseok Kang, MD
Bladder Cancer, Cervical Cancer
Bupropion in Helping Adults Stop Smoking
RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00534001
- Testing
- bupropion hydrochloride
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Roswell Park Cancer Institute
Human Papillomavirus-Related Carcinoma, Oropharyngeal Cancer
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
This is a single arm Phase I study of de-intensified hypofractionated radiation therapy for favorable human papilloma virus-associated oropharynx cancer.
- Trial name
- NCT04580446
- Testing
- Hypofractionated intensity modulated radiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Oral Cavity Neoplasm, Oropharyngeal Neoplasm
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
This randomized phase IIb trial studies how well ACTOplus met extended release (XR) works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment.
- Conditions
- Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT02917629
- Testing
- Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet, Pharmacological Study
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Lip, Oral Cavity Squamous Cell Carcinoma
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck.
- Conditions
- Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx
- Trial name
- NCT03854032
- Testing
- Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Thomas Jefferson University
Oropharyngeal Cancer, Squamous Cell Carcinoma to the Head and Neck
A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.
To assess the efficacy of pregabalin in the management of mucositis pain in patients receiving radiotherapy to the head and neck.
- Trial name
- NCT02277548
- Testing
- Lyrica 300 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
This phase III trial compares the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma
- Trial name
- NCT04458909
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- 325 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy
This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- ENCORE (NCT00700440)
- Testing
- C225 (cetuximab)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
This clinical trial will evaluate a new combination of treatments for Oropharyngeal Squamous Cell cancers (OPSCC), and compare it to the current standard of care (concurrent, platinum-based chemoradiotherapy).
- Trial name
- NCT03715946
- Testing
- Nivolumab Injection, Radiotherapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Robert L. Ferris, MD, PhD
Recurrent Oropharynx Carcinoma
Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer
The purpose of this research project is to measure changes in communication, swallowing and quality of life and individual patient priorities which may happen over time in patients with a diagnosis of recurrent head and neck…
- Trial name
- FUNQOLR (NCT04952922)
- Testing
- Treatment for recurrent oropharyngeal cancer (curative/ palliative)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Nasopharyngeal Carcinoma
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
This study is a multi-center, randomized, open label, Phase III clinical trial for advanced Nasopharyngeal Carcinoma(NPC) Patients.
- Trial name
- VANCE (NCT02578641)
- Testing
- autologous EBV specific Cytotoxic T cells, combination IV gemcitabine and IV carboplatin (AUC2)
- Where
- 30 sites in United States, Malaysia and 3 more
- Volunteers
- 330 people
- Sponsor
- Tessa Therapeutics
Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma
- Trial name
- NCT02113878
- Testing
- BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignancies
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.
- Trial name
- NCT03474640
- Testing
- Part A, Part B
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- TopAlliance Biosciences
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with…
- Conditions
- Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma
- Trial name
- NCT05166577
- Testing
- Nanatinostat, Valganciclovir, Pembrolizumab
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 26 people
- Sponsor
- Viracta Therapeutics, Inc.
Bladder Cancer, Cervical Cancer
Acceptability of Less Harmful Alternatives to Cigarettes
RATIONALE: A study that evaluates participants' beliefs about smokeless tobacco products and nicotine replacement therapy may be useful in helping smokers stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00957424
- Testing
- telephone-based intervention, nicotine replacement therapy, informational intervention
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Roswell Park Cancer Institute
Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic).
- Conditions
- Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7
- Trial name
- NCT02339558
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
HNSCC, Lip SCC
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC.
- Conditions
- HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT03082534
- Testing
- Pembrolizumab, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Diego